Bio-Nanomedicine for Cancer Therapy

The book covers the latest developments in biologically-inspired and derived nanomedicine for cancer therapy. The purpose of the book is to illustrate the significance of naturally-mimicking systems for enhancing the dose delivered to the tumor, to improve stability, and prolong the circulation time. Moreover, readers are presented with advanced materials such as adjuvants for immunostimulation in cancer vaccines. The book also provides a comprehensive overview of the current status of academic research. This is an ideal book for students, researchers, and professors working in nanotechnology, cancer, targeted drug delivery, controlled drug release, materials science, and biomaterials as well as companies developing cancer immunotherapy.

Serves as a guide through biohybrid systems, cell derived nanoparticles, viral derived or mimicking nanosystems and their applications as drug delivery systems and as adjuvants in cancer vaccines Illustrates the importance of biologically-related structures in drug delivery in cancer, as a mean to improve nanotechnology Details how nanotechnology is essential in the discovery and development of novel adjuvants for cancer immunotherapy

Auteur

Hélder A. Santos is a Full Professor in Pharmaceutical Nanotechnology, Principal Investigator/Group Leader, Director of the Doctoral Program in Drug Research, and Head of the Nanomedicines and Biomedical Engineering Group at the Faculty of Pharmacy, University of Helsinki (Finland). He is also the Director of the FinPharmNet and Chair of Controlled Release Society Focus Group in Nanomedicine and Nanoscale Delivery. Prof. Santos' research is focused on nanobiomaterials, nanovaccines, inorganic and and polymeric-based nanomedicines for controlled drug delivery, diagnostics and therapy. The research interests include the development of nanomedicines for biomedical and healthcare applications. His current work makes the bridge between engineering, pharmaceutical and medical research. His main research focus is in the use of biodegradable and biocompatible nanomaterials for simultaneous controlled drug delivery, diagnostic and treatment of cancer, diabetes, and cardiovascular diseases, and ^ 8800 citations, h-index = 56), and more than 260 conference proceedings/abstracts. Flavia Fontana is a postdoctoral fellow at the Faculty of Pharmacy, University of Helsinki, where she gained her PhD in Pharmacy with honors in 2019. F. Fontana is interested in developing smart, biohybrid, materials for immunological applications for the treatment of cancer and autoimmune diseases. So far, she has authored/co-authored 24 papers (original and reviews) and 4 book chapters, while giving 4 oral communications and 3 poster presentations in international scientific meetings. F. Fontana has more than 550 citations (Google scholar 580, h-index=13) and has served as reviewer for 5 international peer-reviewed scientific journals.

Contenu
Part 1.- Conventional nanosized drug delivery systems for cancer applications.- Homing peptides for cancer therapy.- Radiolabeling of theranostic nanosystems.- Boosting nanomedicine efficacy with hyperbaric oxygen therapy.- Part 2.- Mesoporous Silica Nanoparticles as Carriers for Biomolecules in Cancer Therapy.- Clearable Nanoparticles for Cancer Photothermal Therapy.- Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds.- Electrospun Nanofibers for Cancer Therapy.- Nanoneedle-based materials for intracellular studies.- Part 3.- In vitro assays for nanoparticle-cancer cell interaction studies.- 3D tumor spheroid models for in vitro therapeutic screening of nanoparticles.- In vitro and in vivo tumor models for the evaluation of anticancer nanoparticles.- Part 4.- Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.- Viral nanoparticles: cancer vaccines and immune modulators.- Industrial Perspective on Cancer Immunotherapy.- Index. <p